The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials.

[1]  T. Powles,et al.  Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. , 2020, The Lancet. Oncology.

[2]  H. Iwata,et al.  Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial , 2020, The Lancet.

[3]  Craig B. Davis,et al.  Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. , 2020, The New England journal of medicine.

[4]  Y. Bang,et al.  Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. , 2020, JAMA oncology.

[5]  Y. Nishioka,et al.  Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study , 2020, Scientific Reports.

[6]  X. Hou,et al.  Immune-related pneumonitis associated with immune checkpoint inhibitors in lung cancer: a network meta-analysis , 2020, Journal for ImmunoTherapy of Cancer.

[7]  Tingting Liu,et al.  Comparative risk of serious and fatal treatment-related adverse events caused by 19 immune checkpoint inhibitors used in cancer treatment: a network meta-analysis , 2020, Therapeutic advances in medical oncology.

[8]  N. Takebe,et al.  A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy , 2020, Cancer drug resistance.

[9]  P. Ascierto,et al.  Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.

[10]  C. Rudin,et al.  Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Galsky,et al.  Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[12]  Edward S. Kim,et al.  Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer , 2020, JAMA oncology.

[13]  M. Socinski,et al.  Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[15]  N. Reinmuth,et al.  ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  M. Kudo,et al.  Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Winer,et al.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[18]  Young Hak Kim,et al.  Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial , 2019, The Lancet.

[19]  N. Reinmuth,et al.  Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[20]  Linyan Zhu,et al.  Progress in research on paclitaxel and tumor immunotherapy , 2019, Cellular & Molecular Biology Letters.

[21]  E. V. Van Allen,et al.  Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients? , 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[22]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[23]  Emily C. Zhu,et al.  Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis , 2019, Front. Immunol..

[24]  Shanshan Jiang,et al.  The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis , 2018, Front. Pharmacol..

[25]  Jae Ho Lee,et al.  Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. , 2018, Lung cancer.

[26]  D. Schadendorf,et al.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[27]  A. Mansfield,et al.  First‐Line Atezolizumab plus Chemotherapy in Extensive‐Stage Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[28]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[29]  Gregory Riely,et al.  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Federico Cappuzzo,et al.  Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC , 2018, The New England journal of medicine.

[31]  M. Links,et al.  Treatment‐related toxicities of immune checkpoint inhibitors in advanced cancers: A meta‐analysis , 2018, Asia-Pacific journal of clinical oncology.

[32]  P. Cui,et al.  Risk factors for pneumonitis in patients treated with anti‐programmed death‐1 therapy: A case‐control study , 2018, Cancer medicine.

[33]  J. Szustakowski,et al.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden , 2018, The New England journal of medicine.

[34]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[35]  D. Schadendorf,et al.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[36]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[37]  T. Yoshikawa,et al.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[38]  Tarek Mekhail,et al.  Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[39]  J. Krisl,et al.  Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[40]  S. Zhang,et al.  Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis , 2017, Molecular Cancer Therapeutics.

[41]  E. Evron,et al.  Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature , 2017, Journal of chemotherapy.

[42]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[43]  Matthieu Texier,et al.  Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination , 2016, Nature Reviews Clinical Oncology.

[44]  O. Abdel-Rahman,et al.  Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis , 2016, Therapeutic advances in respiratory disease.

[45]  A. Cato,et al.  Effects of Glucocorticoids in the Immune System. , 2015, Advances in experimental medicine and biology.

[46]  N. Agarwal,et al.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. , 2014, The Lancet. Oncology.

[47]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[48]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[49]  M. Arning,et al.  A Report on Serious Pulmonary Toxicity Associated with Gemcitabine-Based Therapy , 2002, Investigational New Drugs.